Member Info for Mulder

Directors do not buy just before a rights issue at a premium of 50%!

4x earnings and short sellers continue to get their way here. Incredible. Directors well down on their recent buys.

Stupid sell off led by the crooks that are short sellers.
ZAR gold price is UP vs 2021
That is what matters not the USD price.
P/E of just FIVE is crazy. Debt free.

Sorry to say the market remains highly irrational and many would say corrupt.

International doing very well. Growth.

Pound at 40 year lows vs USD
Bargain for someone.

Plus M&A

P/E 5

M&A remains a distinct possibility here, one hopes the board is honest and comply with FCA rules in terms of full disclosure of all approaches no matter how hostile or speculative. CEO is under huge pressure after his naive moves so far.

about this share price?
What happened to the deal making?

.

Really?

.

Extreme greed.

Doctors and nurses have saved the lives of thousands of Covid patients over the pandemic and still do today, at great risk to themselves and their own health but their reward is a 4% pay rise - why do RMG employees/postmen feel they deserve more?

As most if not all of those participating in the strike will be shareholders - as shares plummet you become poorer.

Solar plant will also help

FCA need to wake up and get their house in order. Any hedge fund shorting a FTSE stock should be listed on the FCA short tracker and not on overseas sites like Euroclear where these manipulating crooks can hide.

No need for any special dividend!

That's crazy. Should be around P/E 10.

NB: This was when the share price was £13 not £10. Even more of a target now.

Oxford BioMedica PLC (LSE:OXB), Smith & Nephew PLC (LSE:SN) and Spire Healthcare Group Plc (LSE:SPI) are among UK midcap health-care companies "vulnerable” to takeovers from private-equity (PE) firms, investment bank RBC Group says.

The stocks trade below historical multiples and have under-geared balance sheets - making them ripe for "PE firms seemingly well-funded and large trade players having strong balance sheets, and in some cases post-COVID earnings holes to fill," according to the bank.

Trauma and orthopaedic equipment provider Smith & Nephew’s shares are trading “35% below their peak”, the bank said, partly due to the impact of Covid-19 on hospital activity, while its balance sheet is “only modestly geared at 1.6x EBITDA”.

RBC said a consortium of buyers might opt to divest the company's wound care business for a partial return, but with such a hefty price tag, the asset would be likely to come back to the public markets in future.

“A re-IPO could be the potential exit route for PE,” it said.